Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PFIZER INCPFE · Entity 2863 | Executive Vice President | August 13, 2018 | August 14, 2018 |
| Quanterix CorpQTRX · Entity 6649 | Director | May 14, 2024 | May 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PFIZER INC
Report date August 13, 2018 · Filed August 14, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 72,672 |
Reported balance
After 2018-08-13 transaction · row 1
1 source rowRow 1 · 2018-08-13 · Sale · Disposed 10,214 · Balance 72,672 |
| Common StockSEC Table I · non-derivative | IndirectBy Rule 16b-3 Plan | 5,529 |
Reported balance
Holding disclosure · report date 2018-08-13 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,529 |
Quanterix Corp
Report date May 14, 2024 · Filed May 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,738 |
Reported balance
After 2024-05-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-05-14 · Sale · Disposed 1,500 · Balance 13,738 F1: The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2023. F2: Includes 2,947 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2023.
F2: Includes 2,947 restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Karuna Therapeutics, Inc.
Report date March 18, 2024 · Filed March 18, 2024
Section 16 reporting ended · disclosed 2024-03-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 1
1 source rowRow 1 · 2024-03-18 · Disposition to issuer · Disposed 990 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F2: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.86 · Expires 2030-08-11 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-18 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.01 · Expires 2031-06-15 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-18 · Disposition to issuer · Disposed 8,500 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $102.96 · Expires 2032-06-14 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-03-18 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $237.70 · Expires 2033-06-19 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-03-18 · Disposition to issuer · Disposed 1,904 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F5: These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
F2: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.
F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.
F4: These Options are fully vested.
F5: These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 30, 2013 Filed May 1, 2013 22:26 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 34 | $29.07 | $988.38 |
DisclosureSEC source: 0001225208-13-010921 · doc4.xml · derivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137 Underlying: Common Stock · 34 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 15, 2013 Filed Apr 17, 2013 12:11 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 34 | $30.45 | $1,035.30 |
DisclosureSEC source: 0001225208-13-010060 · doc4.xml · derivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103 Underlying: Common Stock · 34 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 28, 2013 Filed Apr 1, 2013 20:20 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 34 | $28.86 | $981.24 |
DisclosureSEC source: 0001225208-13-008779 · doc4.xml · derivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69 Underlying: Common Stock · 34 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 15, 2013 Filed Mar 18, 2013 21:53 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 35 | $28.02 | $980.70 |
DisclosureSEC source: 0001225208-13-007882 · doc4.xml · derivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35 Underlying: Common Stock · 35 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 31,993 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006475 · doc4.xml · derivative · entry 9 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,993 Underlying: Common Stock · 31,993 shares Expires 2020-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 38,546 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006475 · doc4.xml · derivative · entry 8 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,546 Underlying: Common Stock · 38,546 shares Expires 2018-02-28 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionStock Appreciation Rights · Derivative | 11,510 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001225208-13-006475 · doc4.xml · derivative · entry 7 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,510 shares Expires 2013-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Dividend equivalents are paid on these stock appreciation rights at the time of settlement. F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 10,946 | $27.37 | $299,592.02 |
DisclosureSEC source: 0001225208-13-006475 · doc4.xml · nonDerivative · entry 5 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,347 F5 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations and payment of exercise price in connection with the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 3,367 | $27.37 | $92,154.79 |
DisclosureSEC source: 0001225208-13-006475 · doc4.xml · nonDerivative · entry 4 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,293 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 6,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006475 · doc4.xml · nonDerivative · entry 3 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,660 F3 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 9,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006475 · doc4.xml · nonDerivative · entry 2 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,140 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionCommon Stock | 13,368 | $22.55 | $301,448.40 |
DisclosureSEC source: 0001225208-13-006475 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 25, 2013 Filed Feb 27, 2013 00:06 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 2,197 | $26.84 | $58,967.48 |
DisclosureSEC source: 0001225208-13-005615 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,665 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| December 31, 2012 Filed Jan 3, 2013 15:10 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 1,960 | $25.08 | $49,156.80 |
DisclosureSEC source: 0001225208-13-000295 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,644 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| September 13, 2012 Filed Sep 14, 2012 18:13 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 12,900 | $24.01 | $309,729.00 |
DisclosureSEC source: 0001225208-12-019636 · doc4.xml · nonDerivative · entry 2 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,328 Read SEC document |
| September 13, 2012 Filed Sep 14, 2012 18:13 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 2,342 | $24.02 | $56,254.84 |
DisclosureSEC source: 0001225208-12-019636 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,228 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.